Free Cash Flow for Alnylam Pharmaceuticals (ALNY)
Free Cash Flow for Alnylam Pharmaceuticals (ALNY): headline value $465.38M · YoY -1192.7%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingFree Cash FlowSwitch metric
Latest period
$465.38M
YoY change
-1192.7%
5Y CAGR
N/A
Peak year (2025)
$465.38M
Latest annual
$465.38M
Free Cash Flow history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Free Cash Flow history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Free Cash Flow | YoY |
|---|---|---|---|---|
| 2025 | $465.38M | -1192.7% | ||
| 2024 | -$42.59M | -201.5% | ||
| 2023 | $41.95M | -106.8% | ||
| 2022 | -$613.33M | -14.6% | ||
| 2021 | -$718.07M | +4.8% | ||
| 2020 | -$685.32M | +63.7% | ||
| 2019 | -$418.58M | -39.3% | ||
| 2018 | -$689.50M | +41.6% | ||
| 2017 | -$487.00M | +30.8% | ||
| 2016 | -$372.26M | +84.2% | ||
| 2015 | -$202.09M | +15.7% | ||
| 2014 | -$174.60M | +140.3% | ||
| 2013 | -$72.66M | -41.4% | ||
| 2012 | -$123.96M | +40.3% | ||
| 2011 | -$88.36M | -0.8% | ||
| 2010 | -$89.07M | +15.5% | ||
| 2009 | -$77.09M | -240.9% | ||
| 2008 | $54.73M | -71.0% | ||
| 2007 | $188.73M | -737.3% | ||
| 2006 | -$29.62M | +60.7% | ||
| 2005 | -$18.43M | -35.5% | ||
| 2004 | -$28.58M | +79.2% | ||
| 2003 | -$15.95M | +766.7% | ||
| 2002 | -$1.84M | — |
Free Cash Flow values are taken from Alnylam Pharmaceuticals's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Alnylam Pharmaceuticals (ALNY) most recent annual free cash flow stands at $465.38M (2025) – plunged 1192.7% year-over-year.
2025 marks the peak free cash flow at $465.38M, with the historical low of -$718.07M recorded in 2021.
Among 8 Healthcare peers, Alnylam Pharmaceuticals (ALNY) ranks 9th; the peer median for free cash flow is $14.22B.
Alnylam Pharmaceuticals Free Cash Flow by Year
Alnylam Pharmaceuticals Free Cash Flow 2025: $465.38M
Alnylam Pharmaceuticals free cash flow in 2025 was $465.38M, plunged 1192.7% below 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Free Cash Flow 2024: -$42.59M
Alnylam Pharmaceuticals free cash flow in 2024 was -$42.59M, plunged 201.5% below 2023.
Alnylam Pharmaceuticals Free Cash Flow 2023: $41.95M
Alnylam Pharmaceuticals free cash flow in 2023 was $41.95M, plunged 106.8% below 2022.
Alnylam Pharmaceuticals Free Cash Flow 2022: -$613.33M
Alnylam Pharmaceuticals free cash flow in 2022 was -$613.33M, declined 14.6% below 2021.
Alnylam Pharmaceuticals Free Cash Flow 2021: -$718.07M
Alnylam Pharmaceuticals free cash flow in 2021 was -$718.07M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — Free Cash Flow
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest free cash flow.
| Company | Free Cash Flow | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $28.99B | Healthcare |
| Johnson & Johnson (JNJ) | $19.70B | Healthcare |
| AbbVie Inc. (ABBV) | $17.82B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $16.07B | Healthcare |
| Merck & Co., Inc. (MRK) | $12.36B | Healthcare |
| AstraZeneca PLC (AZN) | $11.77B | Healthcare |
| Eli Lilly and Company (LLY) | $8.97B | Healthcare |
| Amgen Inc. (AMGN) | $8.10B | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's free cash flow?
Latest reported free cash flow for Alnylam Pharmaceuticals (ALNY) is $465.38M (period ending December 31, 2025).
How has Alnylam Pharmaceuticals free cash flow changed year-over-year?
Alnylam Pharmaceuticals (ALNY) free cash flow changed -1192.7% year-over-year on the latest annual filing.
When did Alnylam Pharmaceuticals free cash flow hit its highest annual value?
Alnylam Pharmaceuticals free cash flow reached its highest annual value of $465.38M in 2025.
What was Alnylam Pharmaceuticals free cash flow in 2024?
Alnylam Pharmaceuticals (ALNY) free cash flow in 2024 was -$42.59M.
What was Alnylam Pharmaceuticals free cash flow in 2025?
Alnylam Pharmaceuticals (ALNY) free cash flow in 2025 was $465.38M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.